Glucagon-like peptide-1 (GLP-1) receptor agonists have recently become widely used across the US, substantially changing metabolic disease management.1 While regulatory agencies have reported no association between GLP-1 medications and cancer risks, concerns persist among patients, particularly among survivors of cancer and those with a family history of cancer.2,3 To our knowledge, how patients discuss these cancer-related risks on social media has not been extensively studied. This evidence concerns the gene GLP1R and cancer.